Artelo Biosciences, Inc. is a biopharmaceutical company. The Company is focused on licensing, developing and commercializing treatments intended to modulate the endocannabinoid system (ECS). It develops and commercializes ethical pharmaceutical products that provide physicians access to the therapeutic potential of cannabinoid therapeutics and other modulators of the ECS for their patients. Its pipeline includes ART12.11, ART26.12 and ART27.13. The Company is developing ART12.11 for targeting the development in Inflammatory Bowel Disease (IBD), stroke and rare/orphan diseases. ART26.12 is its endocannabinoid transport protein (FABP5) inhibitor for treatment of breast cancer, prostate cancer, and neuropathic and nociceptive pain. ART27.13 is being developed for cancer. The Company also intends to develop a formulation suitable for treatment of anorexia/weight loss associated with cancer (cachexia).